

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: IFT1/22 - Immunophenotypisation

Deadline: 11.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(253) CD 3+ T lymphocytes					30						30	29	97%	
Samples and groups	[%]													
Sample A		80,7	1,3	1,6	30	CVP	80,8	0,27	7%	75,1	86,5	30	29	97%
(12) Beckman Coulter		80,1	1,3	1,6	16	0						16		
(88) Becton Dickinson		80,9	1,2	1,5	7	0						7		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
Sample B		79,4	1,2	1,5	30	CVP	79,4	0,29	7%	73,8	85	30	30	100%
(12) Beckman Coulter		79,1	1,1	1,4	16	0						16		
(88) Becton Dickinson		79,2	1,3	1,7	7	0						7		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
(254) CD 4+ T lymphocytes					30						30	29	97%	
Samples and groups	[%]													
Sample A		44,8	1,4	3,1	30	CVP	44,8	0,33	10%	40,3	49,3	30	29	97%
(12) Beckman Coulter		44,7	1,2	2,7	16	0						16		
(88) Becton Dickinson		43,2	3,0	6,8	7	0						7		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
Sample B		46,2	1,4	3,0	30	CVP	46,5	0,34	10%	41,8	51,2	30	29	97%
(12) Beckman Coulter		46,3	1,0	2,2	16	0						16		
(88) Becton Dickinson		45,8	1,5	3,2	7	0						7		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
(255) CD 8+ T lymphocytes					30						30	29	97%	
Samples and groups	[%]													
Sample A		30,7	2,3	7,6	30	CVP	31,4	0,61	17%	26	36,8	30	30	100%
(12) Beckman Coulter		29,7	2,0	6,6	16	0						16		
(88) Becton Dickinson		31,4	2,5	8,0	7	0						7		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
Sample B		25,1	1,5	6,1	30	CVP	25,3	0,31	17%	20,9	29,7	30	29	97%
(12) Beckman Coulter		24,3	1,2	5,0	16	0						16		
(88) Becton Dickinson		25,7	1,0	4,0	7	0						7		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
(256) B lymphocytes					30						30	30	100%	
Samples and groups	[%]													
Sample A		7,31	0,83	11	30	CVP	7,58	0,18	30%	5,3	9,86	30	30	100%
(12) Beckman Coulter		7,35	0,99	13	17	0						17		
(88) Becton Dickinson		7,30	0,74	10	6	0						6		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
Sample B		10,8	1,1	9,8	30	CVP	11	0,21	30%	7,7	14,3	30	30	100%
(12) Beckman Coulter		10,6	1,0	9,8	17	0						17		
(88) Becton Dickinson		11,0	1,1	10	6	0						6		
Other					7	0						7		
							3x 36, 3x 177, 1x 999							
(257) NK cells					30						30	27	90%	
Samples and groups	[%]													
Sample A		10,4	0,91	8,8	30	CVP	10,3	0,18	26%	7,62	13	30	27	90%
(12) Beckman Coulter		10,5	0,96	9,2	16	0						16		
(88) Becton Dickinson		10,5	0,36	3,4	6	0						6		
Other					8	0						8		
							3x 36, 1x 63, 3x 177, 1x 999							
Sample B		8,19	0,88	11	30	CVP	8,25	0,19	26%	6,1	10,4	30	27	90%
(12) Beckman Coulter		8,44	0,77	9,1	16	0						16		
(88) Becton Dickinson		8,30	1,0	13	6	0						6		
Other					8	0						8		
							3x 36, 1x 63, 3x 177, 1x 999							

st_kn_p

End of report

Printed: 14.04.2022